Market Overview

UPDATE: Piper Jaffray Downgrades Illumina to Neutral on Tough 2H13 Comps

Related ILMN
Goldman Says These 25 Healthcare Stocks Are Immune To The Election
Benzinga's M&A Chatter for Monday, October 17, 2016
Baron Funds Comments on Illumina Inc. (GuruFocus)

In a report published Tuesday, Piper Jaffray analyst William R. Quirk downgraded the rating on Illumina (NASDAQ: ILMN) from Overweight to Neutral, and lowered the price target from $72.00 to $70.00.

In the report, Piper Jaffray noted, “Our downgrade reflects concerns over increasingly more challenging 2H13 comps, likely limiting upside in the back-half of the year, and with the current valuation. We are also adjusting our forward estimates (increasing share count, pulling forward HiSeq upgrade revenue, trimming Verinata), with our updated F2013 and F2014 estimates now $1,349.7M/$1.65 (were $1,340.1M/$1.67) and $1,511.9M/$1.91 (were $1,553.1M/$1.96). We are maintaining our multiple (34x 2014 EPS + net cash/share), yielding a $70 price target (was $72). With ILMN shares trading above our $70 price target, we view shares as fully valued and believe a Neutral rating is more appropriate.”

Illumina closed on Monday at $76.27.

Latest Ratings for ILMN

Oct 2016CitigroupMaintainsNeutral
Oct 2016BarclaysMaintainsEqual-Weight
Oct 2016Janney CapitalDowngradesNeutralSell

View More Analyst Ratings for ILMN
View the Latest Analyst Ratings

Posted-In: Piper Jaffray William R. QuirkAnalyst Color Downgrades Analyst Ratings


Related Articles (ILMN)

View Comments and Join the Discussion!